Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead's HIV prevention treatment found 100% effective in late-stage trial
Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Gilead's long-acting HIV drug superior to daily pill Truvada in study
Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truvada.
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
The latest trading day saw Gilead Sciences (GILD) settling at $63.56, representing a -1.21% change from its previous close.
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining.
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Gilead Sciences is a safe, reliable dividend stock. Organon pays a high dividend yield and has been a big winner for investors this year.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference
Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO.
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
